John J Nemunaitis Selected Research

John J Nemunaitis Research Topics

Disease

22	Neoplasms (Cancer) 01/2022 - 09/2002
7	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 05/2023 - 06/2004
5	Disease Progression 05/2023 - 06/2004
5	Melanoma (Melanoma, Malignant) 01/2019 - 09/2002
3	Squamous Cell Carcinoma of Head and Neck 01/2023 - 01/2018
2	Inflammation (Inflammations) 01/2022 - 12/2015
2	Fatigue 01/2022 - 07/2013
2	Diarrhea 01/2022 - 07/2013
2	Malignant Mesothelioma 01/2020 - 01/2019
2	Ovarian Neoplasms (Ovarian Cancer) 01/2020 - 08/2015
2	Anemia 12/2015 - 07/2013
2	Pancreatic Neoplasms (Pancreatic Cancer) 12/2015 - 04/2015
2	Prostatic Neoplasms (Prostate Cancer) 08/2012 - 07/2006
1	Aseptic Meningitis 01/2022
1	Fever (Fevers) 01/2022
1	Vomiting 01/2022
1	Nausea 01/2022
1	Mesothelioma 01/2019
1	Hypoxia (Hypoxemia) 01/2018
1	Colorectal Neoplasms (Colorectal Cancer) 01/2017
1	Pancreatic Ductal Carcinoma 04/2015
1	Hypersensitivity (Allergy) 12/2014
1	Neutropenia 08/2014
1	Orthostatic Hypotension (Postural Hypotension) 10/2013
1	Lymphopenia (Lymphocytopenia) 07/2013
1	Dyspnea (Shortness of Breath) 07/2013
1	Urinary Bladder Neoplasms (Bladder Cancer) 12/2012
1	Injection Site Reaction 08/2012

Drug/Important Bio-Agent (IBA)

4	VaccinesIBA 08/2012 - 12/2007
3	Paclitaxel (Taxol)FDA LinkGeneric 05/2023 - 06/2004
3	Bevacizumab (Avastin)FDA Link 05/2023 - 06/2004
3	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2018
3	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 12/2016 - 12/2009
2	Carboplatin (JM8)FDA LinkGeneric 05/2023 - 06/2004
2	TH 302IBA 01/2023 - 01/2018
2	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2022
2	PlatinumIBA 01/2019 - 08/2014
2	avelumabIBA 01/2019 - 01/2019
2	Gemcitabine FDA Link 12/2015 - 01/2003
2	Cancer VaccinesIBA 08/2015 - 08/2012
2	Peptides (Polypeptides)IBA 08/2015 - 08/2012
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 08/2014 - 07/2013
2	Toll-Like Receptor 9IBA 08/2014 - 07/2013
2	AntigensIBA 08/2012 - 09/2008
2	Small Interfering RNA (siRNA)IBA 01/2009 - 12/2007
1	itacitinibIBA 01/2022
1	parsaclisibIBA 01/2022
1	Interleukin-2 (IL2)IBA 01/2022
1	InterferonsIBA 01/2022
1	epacadostatIBA 01/2022
1	Blood Proteins (Serum Proteins)IBA 01/2022
1	Interleukin-15 (Interleukin 15)IBA 01/2022
1	Tumor Biomarkers (Tumor Markers)IBA 01/2021
1	anetumab ravtansineIBA 01/2020
1	MesothelinIBA 01/2020
1	Differentiation AntigensIBA 01/2020
1	Maytansine (Maitansine)IBA 01/2020
1	Immunoconjugates (Immunoconjugate)IBA 01/2020
1	IpilimumabIBA 01/2019
1	AntibodiesIBA 01/2019
1	Pemetrexed (MTA)FDA Link 01/2019
1	LigandsIBA 01/2019
1	A-Form DNA (A-DNA)IBA 01/2018
1	Mechlorethamine (Nitrogen Mustard)FDA Link 01/2018
1	ProdrugsIBA 01/2018
1	varlilumabIBA 06/2017
1	Glycoproteins (Glycoprotein)IBA 01/2017
1	tumor-associated antigen 72IBA 01/2017
1	Chimeric Antigen ReceptorsIBA 01/2017
1	talimogene laherparepvecIBA 12/2016
1	ruxolitinibIBA 12/2015
1	C-Reactive ProteinIBA 12/2015
1	Capecitabine (Xeloda)FDA Link 12/2015
1	Janus KinasesIBA 12/2015
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 08/2015
1	SurvivinIBA 08/2015
1	Thymidine KinaseIBA 04/2015
1	Insulin (Novolin)FDA Link 04/2015
1	Ganciclovir (Cytovene)FDA LinkGeneric 04/2015
1	Docetaxel (Taxotere)FDA Link 12/2014
1	ElectrolytesIBA 08/2014
1	IMO-2055IBA 08/2014
1	Uric Acid (Urate)IBA 10/2013
1	Cyclin-Dependent Kinases (cdk Proteins)IBA 10/2013
1	dinaciclibIBA 10/2013
1	ProMune (CpG 7909)IBA 07/2013
1	ErbB Receptors (EGF Receptor)IBA 07/2013
1	EmulsionsIBA 08/2012
1	HLA-A2 Antigen (HLA A2 Antigen)IBA 08/2012
1	DPX-0907IBA 08/2012
1	PolymersIBA 01/2009
1	IDM 2101IBA 09/2008
1	EpitopesIBA 09/2008
1	Neoplasm Antigens (Tumor Antigens)IBA 12/2007
1	DNA (Deoxyribonucleic Acid)IBA 12/2007

Therapy/Procedure

10	Therapeutics 01/2022 - 07/2006
5	Immunotherapy 01/2022 - 09/2008
5	Drug Therapy (Chemotherapy) 01/2022 - 11/2007
1	Radiotherapy 01/2018
1	Premedication 12/2014